Moyi Liu

Title: Moyi Liu - Innovator in Pharmaceutical Chemistry

Introduction

Moyi Liu is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the resolution of chiral compounds. His innovative methods have the potential to enhance the efficacy of pharmaceutical products.

Latest Patents

Moyi Liu holds a patent for a resolution method for axial chiral enantiomers of lesinurad. This method utilizes inexpensive and readily available quinoline natural products and their derivatives as resolving agents. The process involves reacting these agents with lesinurad racemate in an organic solvent to form a salt. This salt is then dissociated through acidification to yield optically pure (R)- or (S)-2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid. The method achieves a chiral purity of up to 100% for the R configuration and a total yield of 90% or more. The S configuration can reach a chiral purity of up to 99.9% with a total yield of 80% or more.

Career Highlights

Moyi Liu is currently associated with China Resources Saike Pharmaceutical Co., Ltd. His work focuses on developing innovative solutions in the pharmaceutical industry. His expertise in resolving chiral compounds has positioned him as a valuable asset in his field.

Collaborations

Moyi Liu collaborates with talented individuals such as Fangze Chi and Yan Yang. Their combined efforts contribute to advancing research and development in pharmaceutical chemistry.

Conclusion

Moyi Liu's contributions to the resolution of chiral enantiomers exemplify the importance of innovation in pharmaceutical chemistry. His work not only enhances the purity of pharmaceutical compounds but also demonstrates the potential for cost-effective solutions in drug development.